益方生物：2025年预亏2.92亿元

Core Viewpoint - The company Yifang Biotech (688382.SH) is expected to report significant losses in 2025, with a projected total profit of -292 million yuan and a net profit attributable to shareholders of -292 million yuan, indicating ongoing financial challenges as it invests heavily in research and development [1][2]. Financial Performance - The company anticipates a revenue of 37.2452 million yuan in 2025, which is below 100 million yuan, reflecting a challenging revenue environment [1]. - The expected net profit after deducting non-recurring gains is projected to be -304 million yuan, indicating a worsening financial outlook [1]. Research and Development Progress - The company is maintaining high levels of R&D investment, with several core clinical projects advancing to critical stages, including the D-0502 SERD in Phase III trials and D-2570 TYK2 inhibitor in multiple clinical explorations [1][2]. - Two innovative preclinical candidates, YF087 and YF550, are showing promising anti-tumor potential and are undergoing IND supportive research to prepare for clinical stages [2]. Revenue Sources and Business Model - The current revenue primarily comes from licensing and collaboration, which varies year to year, leading to fluctuations in income that do not cover costs and expenses, resulting in continued losses for 2025 [2]. - Despite the financial losses, the company's core business and competitive strengths remain intact, indicating potential for future recovery as R&D progresses [2].